Spots Global Cancer Trial Database for Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent

Official Title: Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent

Study ID: NCT02602990

Conditions

Cerebral Arteriovenous Malformations

Interventions

SQUID™

Study Description

Brief Summary: A non-interventional multicentric study for patients with a cerebral AVM for which endovascular treatment is indicated.

Detailed Description: This observational study will collect data about the treatment of ruptured, unruptured, untreated or endovascular previously treated AVM's. Primary endpoint is safety. Safety will be assessed with the number of procedure-related complications occurring during the endovascular treatment until 30 days after the final embolization. Secondary endpoint is efficacy. Efficacy will be assessed by angiography and clinical outcome assessments (mRS). For each patient enrolled, data will be collected at inclusion, at each embolization session and at 6 ± 1 months after the end of the endovascular treatment phase.